Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GSK1838705A |
Synonyms | |
Therapy Description |
GSK1838705A inhibits IGF-1R, potentially leading to increased apoptosis and reduced tumor growth (PMID: 25926740, PMID: 31181647). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GSK1838705A | IGF-1R Inhibitor 17 | GSK1838705A inhibits IGF-1R, potentially leading to increased apoptosis and reduced tumor growth (PMID: 25926740, PMID: 31181647). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK A348D | hematologic cancer | sensitive | GSK1838705A | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ALK A348D were sensitive to treatment with GSK1838705A in culture, demonstrating decreased cell viability (PMID: 26032424). | 26032424 |
ALK F856S | hematologic cancer | sensitive | GSK1838705A | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ALK F856S were sensitive to treatment with GSK1838705A in culture, demonstrating decreased cell viability (PMID: 26032424). | 26032424 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|